Key Developments

In April 2023, Biosynex SA, a France-based market leader in rapid test design and distribution, announced that it had completed the acquisition of Chembio Diagnostics, Inc., a leading point-of-care diagnostics firm focused on infectious diseases. Chembio already has multiple FDA-approved products (510k, PMA, and CLIA waived products). It is also recognized in the rapid HIV test market with WHO-prequalified products, which will provide Biosynex SA with additional international commercial opportunities.
In March 2023, Trinity Biotech plc, a major developer and manufacturer of diagnostic products for the point-of-care and clinical laboratory markets, welcomed the Kenyan Ministry of Health's announcement of the implementation of a new HIV fast testing algorithm. This new algorithm designates Trinity Biotech's TrinScreen HIV as the screening test (A1 = screen test according to World Health Organization recommendations).
In February 2023, The Kyrgyz Ministry of Health, Neman-Pharm, a retail pharmacy chain, and the U.S. Agency for International Development (USAID) are working together to provide free HIV self-testing kits. The kits will be offered at 32 pharmacies in Bishkek, Osh, and throughout the Chui and Osh regions of the Kyrgyz Republic. The new distribution strategy intends to enhance access to HIV testing for the most vulnerable and hard-to-reach populations.
In July 2022, MedAccess, a social enterprise dedicated to promoting health in low- and middle-income countries, the Clinton Health Access Initiative (CHAI), a global health organization, and Wondfo, a rapidly growing biotechnology company, have announced a partnership to make Wondfo's HIV self-test available for USD 1. The price is more than 30% lower than the current lowest-priced World Health Organization (WHO) prequalified test and 50% less than the most extensively utilized test. This makes Wondfo's HIV self-test the least expensive WHO prequalified self-test on the market.